PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Blood

Volumn 124, Issue 10, 2014, Pages 1626-1636

  Tessoulin, Benoît ^a,b,c,d   Descamps, Géraldine ^a,b,c   Moreau, Philippe ^a,b,c,d   Maïga, Sophie ^a,b,c   Lodé, Laurence ^a,b,c,d   Godon, Catherine ^d   Marionneau Lambot, Séverine ^e   Oullier, Thibauld ^e   Le Gouill, Steven ^a,b,c,d   Amiot, Martine ^a,b,c,d   Pellat Deceunynck, Catherine ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CNRS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e Plate forme in vivo   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; CASPASE 2; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DEATH RECEPTOR 5; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE SYNTHASE; NUTLIN 3; P53 REACTIVATION AND INDUCTION OF MASSIVE APOPTOSIS 1 MET; PROCASPASE 3; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; 2 HYDROXYMETHYL 2 METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN 3 ONE; 2-HYDROXYMETHYL-2-METHOXYMETHYLAZABICYCLO(2.2.2)OCTAN-3-ONE; ANTINEOPLASTIC AGENT; QUINUCLIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CANCER GROWTH; CELL DEATH; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 17P; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENOME; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROENVIRONMENT; MOUSE; MYELOMA CELL; NONHUMAN; POINT MUTATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CELLS, CULTURED; FEMALE; GLUTATHIONE; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; QUINUCLIDINES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907007279     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-548800     Document Type: Article

References (41)

1. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157-2165.
2. Xu-Monette ZY, Medeiros LJ, Li Y, et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood. 2012;119(16):3668-3683.
3. Munshi NC, Anderson KC, Bergsagel PL, et al; International Myeloma Workshop Consensus Panel 2. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011;117(18):4696-4700.
4. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634.
5. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24(10):1769-1778.
6. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92(3):802-809.
7. Schilling G, Hansen T, Shimoni A, et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2008;22(6):1250-1255.
8. Lodé L, Eveillard M, Trichet V, et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica. 2010;95(11):1973-1976.
9. Bodet L, Gomez-Bougie P, Touzeau C, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood. 2011;118(14):3901-3910.
10. Touzeau C, Dousset C, Le Gouill S, et al. The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia. 2014;28(1):210-212.
11. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010;2(9):a001222.
12. Selivanova G. Therapeutic targeting of p53 by small molecules. Semin Cancer Biol. 2010;20(1):46-56.
13. Brown CJ, Cheok CF, Verma CS, Lane DP. Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci. 2011;32(1):53-62.
14. Liu YY. Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors. Cancer Res. 2011;71(20):6295-6299.
15. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8(3):282-288.
16. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15(5):376-388.
17. Lehmann S, Bykov VJ, Ali D, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol. 2012;30(29):3633-3639.
18. Grinter SZ, Liang Y, Huang SY, Hyder SM, Zou X. An inverse docking approach for identifying new potential anti-cancer targets. J Mol Graph Model. 2011;29(6):795-799.
19. Ali D, Jönsson-Videsäter K, Deneberg S, et al. APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells. Eur J Haematol. 2011;86(3):206-215.
20. Russo D, Ottaggio L, Foggetti G, et al. PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. Biochim Biophys Acta. 2013;1833(8):1904-1913.
21. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Ther. 2013;12(11):2331-2341.
22. Chiron D, Maïga S, Surget S, et al. Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J. 2013;3:e120.
23. Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574-582.
24. Surget S, Chiron D, Gomez-Bougie P, et al. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res. 2012;72(17):4562-4573.
25. Chiron D, Surget S, Maïga S, et al. The peripheral CD138+ population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukaemia patients. Br J Haematol. 2012;156(5):679-683.
26. Surget S, Lemieux-Blanchard E, Maiga S, et al. Bendamustine and melphalan similarly kill myeloma cells through ROS production and activation of the p53 pathway and do not overcome resistance to each other [published online ahead of print February 17, 2014]. Leuk Lymphoma.
27. Menoret E, Gomez-Bougie P, Geffroy-Luseau A, et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood. 2006;108(4):1346-1352.
28. Descamps G, Gomez-Bougie P, Tamburini J, et al. The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. Br J Cancer. 2012;106(10):1660-1667.
29. Chiron D, Maïga S, Descamps G, et al. Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells Mol Dis. 2012;48(4):247-253.
30. Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830(5):3143-3153.
31. Siemann DW, Beyers KL. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br J Cancer. 1993;68(6):1071-1079.
32. Kakuni M, Morita M, Matsuo K, et al. Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury. Toxicol Lett. 2012;214(1):9-18.
33. Bykov VJ, Issaeva N, Selivanova G, Wiman KG. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis. 2002;23(12):2011-2018.
34. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-848.
35. Peng X, Zhang MQ, Conserva F, et al. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013;4:e881.
36. Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol. 2010;89(2):191-199.
37. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant. 2002;30(3):135-140.
38. Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia. 2004;6(3):195-206.
39. Muldoon LL, Walker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC, Neuwelt EA. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Ther. 2001;296(3):797-805.
40. Bailey HH, Ripple G, Tutsch KD, et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst. 1997;89(23):1789-1796.
41. Gallo JM, Brennan J, Hamilton TC, et al. Timedependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. Cancer Res. 1995;55(20):4507-4511.